Skip to content
Home » Pharmaceutical company AbbVie buying ImmunoGen in $10.1 billion deal

Pharmaceutical company AbbVie buying ImmunoGen in $10.1 billion deal

    AbbVie is buying ImmunoGen in a deal valued at about $10.1 billion with the goal of speeding the pharmaceutical's entry into the commercial market for ovarian cancer. ImmunoGen Inc. has the ovarian cancer treatment Elahere. "The acquisition of ImmunoGen demonstrates our commitment to deliver on our long-term growth strategy and enables AbbVie to further diversify our oncology pipeline across solid tumors and hematologic malignancies,” AbbVie Chairman and CEO Richard Gonzalez said in a statement on Thursday.

    Read full NASCAR article on Yahoo Sports

    Read all NASCAR articles